

Sarcoma Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



Sarcoma

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

First Line

EA7211

Surgery + Doxorubicin, Ifosfamide or
Doxorubicin, Decarbazine

Coord: B. Huynh

Accrual: 0/5

Second Line

Recurrent

ETCTN 10556

Ipilimumab and Nivolumab +/-
Cabozantinib

Coord: B. Huynh

Accrual: 3/5

UCI 24-08

SPEDOX -6 (Protein encapsulated
doxorubicin)

Coord: E. Palmer-Torrison

Accrual: 4/50